{"id":"https://openalex.org/W4361889445","doi":"https://doi.org/10.1158/1078-0432.22478573","title":"Supplementary Figure S4 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes","display_name":"Supplementary Figure S4 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361889445","doi":"https://doi.org/10.1158/1078-0432.22478573"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22478573","doi":"https://doi.org/10.1158/1078-0432.22478573","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22478573","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_Tarloxotinib_Is_a_Hypoxia-Activated_Pan-HER_Kinase_Inhibitor_Active_Against_a_Broad_Range_of_HER-Family_Oncogenes/22478573/1/files/39930074.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_Tarloxotinib_Is_a_Hypoxia-Activated_Pan-HER_Kinase_Inhibitor_Active_Against_a_Broad_Range_of_HER-Family_Oncogenes/22478573/1/files/39930074.pdf","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022348436","display_name":"Adriana Estrada\u2010Bernal","orcid":"https://orcid.org/0000-0002-0555-2766","observed_orcids":["https://orcid.org/0000-0002-0555-2766"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adriana Estrada-Bernal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100753119","display_name":"Anh Tuan Le","orcid":"https://orcid.org/0000-0003-4221-0914","observed_orcids":["https://orcid.org/0000-0003-4221-0914"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anh T. Le","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4221-0914","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004389580","display_name":"Andrea E. Doak","orcid":"https://orcid.org/0000-0002-7325-6889","observed_orcids":["https://orcid.org/0000-0002-7325-6889"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea E. Doak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037183800","display_name":"Vijaya G. Tirunagaru","orcid":"https://orcid.org/0000-0002-6505-8858","observed_orcids":["https://orcid.org/0000-0002-6505-8858"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vijaya G. Tirunagaru","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051692752","display_name":"Shevan Silva","orcid":"https://orcid.org/0000-0002-9942-1897","observed_orcids":["https://orcid.org/0000-0002-9942-1897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shevan Silva","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9942-1897","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082738447","display_name":"Matthew R. Bull","orcid":"https://orcid.org/0000-0002-9388-0021","observed_orcids":["https://orcid.org/0000-0002-9388-0021"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew R. Bull","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030727604","display_name":"Jeff Bruce Smaill","orcid":"https://orcid.org/0000-0003-2954-6093","observed_orcids":["https://orcid.org/0000-0003-2954-6093"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeff B. Smaill","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2954-6093","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024840477","display_name":"Adam Vorn Patterson","orcid":"https://orcid.org/0000-0001-5138-1227","observed_orcids":["https://orcid.org/0000-0001-5138-1227"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adam V. Patterson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5138-1227","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100741251","display_name":"Chul Kim","orcid":"https://orcid.org/0000-0003-0191-8684","observed_orcids":["https://orcid.org/0000-0003-0191-8684"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chul Kim","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0191-8684","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043871151","display_name":"Stephen V. Liu","orcid":"https://orcid.org/0000-0002-4852-3914","observed_orcids":["https://orcid.org/0000-0002-4852-3914"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen V. Liu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4852-3914","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert C. Doebele","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6728-6857","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.951200008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.951200008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.027400000020861626,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6959999799728394},{"id":"https://openalex.org/keywords/hypoxia-activated-prodrug","display_name":"hypoxia-activated prodrug","score":0.8740000128746033},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.8109999895095825},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mutant-egfr","display_name":"mutant EGFR","score":0.4959999918937683},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.45500001311302185}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.7549419403076172},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.6603327989578247},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5132057666778564},{"id":"https://openalex.org/C7836513","wikidata":"https://www.wikidata.org/wiki/Q1641506","display_name":"Hypoxia (environmental)","level":3,"score":0.48039084672927856},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39558011293411255},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35388708114624023},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.31767737865448},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.313153475522995},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.21058392524719238},{"id":"https://openalex.org/C540031477","wikidata":"https://www.wikidata.org/wiki/Q629","display_name":"Oxygen","level":2,"score":0.055569350719451904},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.22478573","doi":"https://doi.org/10.1158/1078-0432.22478573","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22478573","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_Tarloxotinib_Is_a_Hypoxia-Activated_Pan-HER_Kinase_Inhibitor_Active_Against_a_Broad_Range_of_HER-Family_Oncogenes/22478573/1/files/39930074.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22478573","doi":"https://doi.org/10.1158/1078-0432.22478573","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22478573","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_Tarloxotinib_Is_a_Hypoxia-Activated_Pan-HER_Kinase_Inhibitor_Active_Against_a_Broad_Range_of_HER-Family_Oncogenes/22478573/1/files/39930074.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8560000061988831,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361889445.pdf","grobid_xml":"https://content.openalex.org/works/W4361889445.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3115703756","https://openalex.org/W4361958246","https://openalex.org/W2982154817","https://openalex.org/W2982083339","https://openalex.org/W3185304886","https://openalex.org/W4387812350","https://openalex.org/W2786975350","https://openalex.org/W2955541041","https://openalex.org/W3135184108","https://openalex.org/W2954643241"],"abstract_inverted_index":{"Tarloxotinib":[0],"(prodrug)":[1],"is":[2],"less":[3],"effective":[4],"against":[5],"WT":[6],"and":[7,12],"mutant":[8],"forms":[9],"of":[10],"EGFR":[11],"HER2.":[13]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}